Angina (Angina Pectoris) (Cardiovascular) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina – Drugs In Development, 2021, provides an overview of the Angina (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Angina (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 7, 5, 1 and 5 respectively.

Angina (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Angina (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Angina (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Angina (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Angina (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Angina (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Angionetics Inc

Arbor Pharmaceuticals LLC

AstraZeneca Plc

Caladrius Biosciences Inc

Chong Kun Dang Pharmaceutical Corp

Coeurative Inc

Curacle Co Ltd

Eight Plus One Pharmaceutical Co Ltd

G. Pohl-Boskamp GmbH & Co KG

Hemostemix Inc

Imbria Pharmaceuticals Inc

Innovative Pharmacological Research (IPHAR) Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Kuhnil Pharmaceutical Co Ltd

Merck & Co Inc

Milestone Pharmaceuticals Inc

Signal Pharma Ltd

Trizell Ltd

TSH Biopharm Corporation Ltd

VasThera Co Ltd

XyloCor Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Angina (Angina Pectoris) - Overview

Angina (Angina Pectoris) - Therapeutics Development

Angina (Angina Pectoris) - Therapeutics Assessment

Angina (Angina Pectoris) - Companies Involved in Therapeutics Development

Angina (Angina Pectoris) - Drug Profiles

Angina (Angina Pectoris) - Dormant Projects

Angina (Angina Pectoris) - Discontinued Products

Angina (Angina Pectoris) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Angina (Angina Pectoris), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Angina (Angina Pectoris) – Pipeline by Angionetics Inc, 2021

Angina (Angina Pectoris) – Pipeline by Arbor Pharmaceuticals LLC, 2021

Angina (Angina Pectoris) – Pipeline by AstraZeneca Plc, 2021

Angina (Angina Pectoris) – Pipeline by Caladrius Biosciences Inc, 2021

Angina (Angina Pectoris) – Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021

Angina (Angina Pectoris) – Pipeline by Coeurative Inc, 2021

Angina (Angina Pectoris) – Pipeline by Curacle Co Ltd, 2021

Angina (Angina Pectoris) – Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2021

Angina (Angina Pectoris) – Pipeline by G. Pohl-Boskamp GmbH & Co KG, 2021

Angina (Angina Pectoris) – Pipeline by Hemostemix Inc, 2021

Angina (Angina Pectoris) – Pipeline by Imbria Pharmaceuticals Inc, 2021

Angina (Angina Pectoris) – Pipeline by Innovative Pharmacological Research (IPHAR) Co Ltd, 2021

Angina (Angina Pectoris) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Angina (Angina Pectoris) – Pipeline by Kuhnil Pharmaceutical Co Ltd, 2021

Angina (Angina Pectoris) – Pipeline by Merck & Co Inc, 2021

Angina (Angina Pectoris) – Pipeline by Milestone Pharmaceuticals Inc, 2021

Angina (Angina Pectoris) – Pipeline by Signal Pharma Ltd, 2021

Angina (Angina Pectoris) – Pipeline by Trizell Ltd, 2021

Angina (Angina Pectoris) – Pipeline by TSH Biopharm Corporation Ltd, 2021

Angina (Angina Pectoris) – Pipeline by VasThera Co Ltd, 2021

Angina (Angina Pectoris) – Pipeline by XyloCor Therapeutics Inc, 2021

Angina (Angina Pectoris) – Dormant Projects, 2021

Angina (Angina Pectoris) – Dormant Projects, 2021 (Contd..1)

Angina (Angina Pectoris) – Dormant Projects, 2021 (Contd..2)

Angina (Angina Pectoris) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Angina (Angina Pectoris), 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports